Exact Sciences Corporation
EXAS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.96 | -8.12 | 0.59 |
| FCF Yield | 0.72% | 0.24% | -5.02% | -1.78% |
| EV / EBITDA | -15.85 | 364.80 | -28.28 | -24.93 |
| Quality | ||||
| ROIC | -19.03% | -3.60% | -9.74% | -9.55% |
| Gross Margin | 69.55% | 73.83% | 72.44% | 74.04% |
| Cash Conversion Ratio | -0.20 | -0.76 | 0.36 | 0.17 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.80% | 12.26% | 11.80% | 26.34% |
| Free Cash Flow Growth | 133.48% | 107.29% | -84.04% | -429.96% |
| Safety | ||||
| Net Debt / EBITDA | -2.73 | 46.55 | -5.70 | -3.35 |
| Interest Coverage | -32.80 | -8.80 | -29.42 | -44.90 |
| Efficiency | ||||
| Inventory Turnover | 5.17 | 5.13 | 4.86 | 4.37 |
| Cash Conversion Cycle | 64.57 | 56.88 | 55.22 | 74.32 |